FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3135596931> ?p ?o ?g. }

• W3135596931 endingPage "1564" @default.
• W3135596931 startingPage "1552" @default.
• W3135596931 abstract "Abstract Azacitidine + venetoclax, decitabine + venetoclax, and low-dose cytarabine + venetoclax are now standard treatments for newly diagnosed older or unfit patients with acute myeloid leukemia (AML). Although these combinations are also commonly used in relapsed or refractory AML (RR-AML), clinical and molecular predictors of response and survival in RR-AML are incompletely understood. We retrospectively analyzed clinical and molecular characteristics and outcomes for 86 patients with RR-AML who were treated with venetoclax combinations. The complete remission (CR) or CR with incomplete hematologic recovery (CRi) rate was 24%, and the overall response rate was 31% with the inclusion of a morphologic leukemia-free state. Azacitidine + venetoclax resulted in higher response rates compared with low-dose cytarabine + venetoclax (49% vs 15%; P = .008). Median overall survival (OS) was 6.1 months, but it was significantly longer with azacitidine + venetoclax compared with low-dose cytarabine + venetoclax (25 vs 3.9 months; P = .003). This survival advantage of azacitidine + venetoclax over low-dose cytarabine + venetoclax persisted when patients were censored for subsequent allogeneic stem cell transplantation (8.1 vs 3.9 months; P = .035). Mutations in NPM1 were associated with higher response rates, whereas adverse cytogenetics and mutations in TP53, KRAS/NRAS, and SF3B1 were associated with worse OS. Relapse was driven by diverse mechanisms, including acquisition of novel mutations and an increase in cytogenetic complexity. Venetoclax combination therapy is effective in many patients with RR-AML, and pretreatment molecular characteristics may predict outcomes. Trials that evaluate novel agents in combination with venetoclax therapy in patients with RR-AML that have adverse risk genomic features are warranted." @default.
• W3135596931 created "2021-03-15" @default.
• W3135596931 creator A5001124933 @default.
• W3135596931 creator A5006133411 @default.
• W3135596931 creator A5013969487 @default.
• W3135596931 creator A5025595346 @default.
• W3135596931 creator A5025660159 @default.
• W3135596931 creator A5041740502 @default.
• W3135596931 creator A5044518913 @default.
• W3135596931 creator A5048815063 @default.
• W3135596931 creator A5053461471 @default.
• W3135596931 creator A5055506298 @default.
• W3135596931 creator A5059283771 @default.
• W3135596931 creator A5061509600 @default.
• W3135596931 creator A5066934816 @default.
• W3135596931 creator A5071975128 @default.
• W3135596931 creator A5072492170 @default.
• W3135596931 creator A5074883700 @default.
• W3135596931 creator A5079953387 @default.
• W3135596931 creator A5081153667 @default.
• W3135596931 creator A5083593716 @default.
• W3135596931 date "2021-03-09" @default.
• W3135596931 modified "2023-10-11" @default.
• W3135596931 title "Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML" @default.
• W3135596931 cites W2024748833 @default.
• W3135596931 cites W2037921517 @default.
• W3135596931 cites W2339658711 @default.
• W3135596931 cites W2463060132 @default.
• W3135596931 cites W2559537906 @default.
• W3135596931 cites W2774533007 @default.
• W3135596931 cites W2793886497 @default.
• W3135596931 cites W2800327377 @default.
• W3135596931 cites W2894848403 @default.
• W3135596931 cites W2898284215 @default.
• W3135596931 cites W2914370117 @default.
• W3135596931 cites W2922692686 @default.
• W3135596931 cites W2953259441 @default.
• W3135596931 cites W2953821439 @default.
• W3135596931 cites W2980911308 @default.
• W3135596931 cites W2999354194 @default.
• W3135596931 cites W3000515035 @default.
• W3135596931 cites W3001120382 @default.
• W3135596931 cites W3024552410 @default.
• W3135596931 cites W3030216611 @default.
• W3135596931 cites W3040121048 @default.
• W3135596931 cites W3048827006 @default.
• W3135596931 cites W3069119239 @default.
• W3135596931 cites W3080879632 @default.
• W3135596931 cites W3083003645 @default.
• W3135596931 doi "https://doi.org/10.1182/bloodadvances.2020003734" @default.
• W3135596931 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7948282" @default.
• W3135596931 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33687434" @default.
• W3135596931 hasPublicationYear "2021" @default.
• W3135596931 type Work @default.
• W3135596931 sameAs 3135596931 @default.
• W3135596931 citedByCount "79" @default.
• W3135596931 countsByYear W31355969312021 @default.
• W3135596931 countsByYear W31355969312022 @default.
• W3135596931 countsByYear W31355969312023 @default.
• W3135596931 crossrefType "journal-article" @default.
• W3135596931 hasAuthorship W3135596931A5001124933 @default.
• W3135596931 hasAuthorship W3135596931A5006133411 @default.
• W3135596931 hasAuthorship W3135596931A5013969487 @default.
• W3135596931 hasAuthorship W3135596931A5025595346 @default.
• W3135596931 hasAuthorship W3135596931A5025660159 @default.
• W3135596931 hasAuthorship W3135596931A5041740502 @default.
• W3135596931 hasAuthorship W3135596931A5044518913 @default.
• W3135596931 hasAuthorship W3135596931A5048815063 @default.
• W3135596931 hasAuthorship W3135596931A5053461471 @default.
• W3135596931 hasAuthorship W3135596931A5055506298 @default.
• W3135596931 hasAuthorship W3135596931A5059283771 @default.
• W3135596931 hasAuthorship W3135596931A5061509600 @default.
• W3135596931 hasAuthorship W3135596931A5066934816 @default.
• W3135596931 hasAuthorship W3135596931A5071975128 @default.
• W3135596931 hasAuthorship W3135596931A5072492170 @default.
• W3135596931 hasAuthorship W3135596931A5074883700 @default.
• W3135596931 hasAuthorship W3135596931A5079953387 @default.
• W3135596931 hasAuthorship W3135596931A5081153667 @default.
• W3135596931 hasAuthorship W3135596931A5083593716 @default.
• W3135596931 hasBestOaLocation W31355969311 @default.
• W3135596931 hasConcept C104317684 @default.
• W3135596931 hasConcept C126322002 @default.
• W3135596931 hasConcept C143998085 @default.
• W3135596931 hasConcept C150194340 @default.
• W3135596931 hasConcept C190727270 @default.
• W3135596931 hasConcept C2483381 @default.
• W3135596931 hasConcept C2776239401 @default.
• W3135596931 hasConcept C2777938653 @default.
• W3135596931 hasConcept C2778041864 @default.
• W3135596931 hasConcept C2778461978 @default.
• W3135596931 hasConcept C2778729363 @default.
• W3135596931 hasConcept C2779675984 @default.
• W3135596931 hasConcept C2780235182 @default.
• W3135596931 hasConcept C30481170 @default.
• W3135596931 hasConcept C53226629 @default.
• W3135596931 hasConcept C55493867 @default.
• W3135596931 hasConcept C71924100 @default.
• W3135596931 hasConcept C86803240 @default.

• next